Inhibition of JAK1/STAT3 signaling mediates compound K-induced apoptosis in human multiple myeloma U266 cells
- PMID: 21420464
- DOI: 10.1016/j.fct.2011.03.021
Inhibition of JAK1/STAT3 signaling mediates compound K-induced apoptosis in human multiple myeloma U266 cells
Abstract
Signal transducer and activator of transcription 3 (STAT3) is an oncogenic transcription factor implicated in carcinogenesis. Here, the role of STAT3 pathway in the antitumor activity of an active ginseng saponin metabolite compound K (CK) was investigated in human multiple myeloma U266 cells. CK increased the cytotoxicity, accumulated the sub-G1 DNA population, cleaved poly (ADP-ribose) polymerase (PARP) and activated caspase-3 in U266 cells. Interestingly, CK inhibited phosphorylation of STAT3 and its upstream activators, the Janus activated kinase 1 (JAK1), but not JAK2. Furthermore, CK enhanced the expression of protein tyrosine phosphatase (PTP) SHP-1, but not PTEN. Additionally, CK down-regulated STAT3 target genes bcl-x(L), bcl-2, survivin, cyclin E and cyclin D1. Conversely, PTP inhibitor pervanadate reversed CK-mediated STAT3 inactivation and cleavages of caspase-3 and PARP. Overall, our findings demonstrate that JAK1/STAT3 signaling mediates CK-induced apoptosis in U266 cells and also suggest the chemopreventive potential of CK for treatment of multiple myeloma.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Embelin suppresses STAT3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase PTEN.Cancer Lett. 2011 Sep 1;308(1):71-80. doi: 10.1016/j.canlet.2011.04.015. Epub 2011 May 12. Cancer Lett. 2011. PMID: 21565443
-
Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.Eur J Pharmacol. 2011 Mar 1;654(1):10-6. doi: 10.1016/j.ejphar.2010.11.032. Epub 2010 Dec 21. Eur J Pharmacol. 2011. PMID: 21172343
-
Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation.Clin Cancer Res. 2007 May 15;13(10):3024-32. doi: 10.1158/1078-0432.CCR-06-2575. Clin Cancer Res. 2007. PMID: 17505005
-
Research progress of multi-target HDAC inhibitors blocking the BRD4-LIFR-JAK1-STAT3 signaling pathway in the treatment of cancer.Bioorg Med Chem. 2024 Aug 1;110:117827. doi: 10.1016/j.bmc.2024.117827. Epub 2024 Jul 2. Bioorg Med Chem. 2024. PMID: 38964169 Review.
-
The role of STAT3 signaling in mediating tumor resistance to cancer therapy.Curr Drug Targets. 2014;15(14):1341-53. doi: 10.2174/1389450115666141120104146. Curr Drug Targets. 2014. PMID: 25410411 Review.
Cited by
-
Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells.J Pharmacol Exp Ther. 2015 Sep;354(3):448-58. doi: 10.1124/jpet.115.224766. Epub 2015 Jul 10. J Pharmacol Exp Ther. 2015. PMID: 26163548 Free PMC article.
-
Functional Mechanism of Ginsenoside Compound K on Tumor Growth and Metastasis.Integr Cancer Ther. 2022 Jan-Dec;21:15347354221101203. doi: 10.1177/15347354221101203. Integr Cancer Ther. 2022. PMID: 35615883 Free PMC article. Review.
-
Anticancer Activities of Protopanaxadiol- and Protopanaxatriol-Type Ginsenosides and Their Metabolites.Evid Based Complement Alternat Med. 2016;2016:5738694. doi: 10.1155/2016/5738694. Epub 2016 Jun 30. Evid Based Complement Alternat Med. 2016. PMID: 27446225 Free PMC article. Review.
-
The effects of Ginsenosides on PI3K/AKT signaling pathway.Mol Biol Rep. 2022 Jul;49(7):6701-6716. doi: 10.1007/s11033-022-07270-y. Epub 2022 Feb 27. Mol Biol Rep. 2022. PMID: 35220526 Free PMC article. Review.
-
A narrative review of the pharmacology of ginsenoside compound K.Ann Transl Med. 2022 Feb;10(4):234. doi: 10.21037/atm-22-501. Ann Transl Med. 2022. PMID: 35280413 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous